Drugs / CancerVax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00052130 | — | melanoma | CancerVax Corporation | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2026-08-06 | CancerVax Corporation | Results CancerVax Achieves Major Milestone in Activating Human Killer T-Cells Against Cancer cancervax.com ↗
In-vitro studies confirmed that the Company’s revolutionary therapy successfully disguised liver cancer cells as virally infected cells and activated pre-existing human antiviral Killer T-cells |
| 2026-07-14 | CancerVax Corporation | Results CancerVax Develops Novel Smart mRNA to Harness Pre-Existing Immunity in 99% of World Population cancervax.com ↗
Our recent in vitro results provide encouraging validation of this strategy and represent an important step toward a broadly applicable cancer immunotherapy platform. |
| 2026-06-15 | CancerVax Corporation | Results CancerVax Successfully Demonstrates Full Nanoparticle Delivery in Mouse Study cancervax.com ↗
today announced that the first ever biodistribution study of its complete novel lipid nanoparticle (“LNP”) in mice was successful. |
| 2026-03-31 | CancerVax Corporation | Results CancerVax Reports Successful Initial Mouse Study with Breakthrough Results cancervax.com ↗
CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that the initial biodistribution study of its targeted lipid nanoparticle (“LNP”) in mice was successful. |
| 2025-12-17 | CancerVax Corporation | Results CancerVax Reports Nanoparticle Component Success in Preparation for Animal Studies cancervax.com ↗
In recent in-vitro studies using pancreatic and liver cancer cell lines, the Company received two compelling results that provided confidence in moving forward with animal studies using tumor bearing mice. |
| 2025-10-14 | CancerVax Corporation | Results CancerVax Precision Therapy Successfully Avoids Healthy Liver Cells cancervax.com ↗ |
| 2025-08-19 | CancerVax Corporation | Results Scientists Discuss the Recent CancerVax Breakthrough cancervax.com ↗
This validates our major foundational hypothesis. |
| 2025-08-05 | CancerVax Corporation | Results CancerVax Successfully Disguises Cancer Cells and Tricks Immune Cells into Attacking Them cancervax.com ↗
Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune cells into attacking the malignant cells |
| 2025-06-19 | CancerVax Corporation | Results CancerVax Nanoparticle Successfully Targets Cancer Cells While Sparing Non-cancerous Cells cancervax.com ↗
Recent lab results confirmed that these nanoparticles entered Marker1-positive cancer cells with great efficiency, while avoiding non-cancerous cells lacking the marker. |
| 2025-02-25 | CancerVax Corporation | Results CancerVax Announces Successful Tests of its Smart mRNA Technology cancervax.com ↗
CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the body’s immune system to treat cancer, today announced the successful functional validation of its innovative Smart mRNA (messenger RNA) technology in lab tests. |
| 2024-04-03 | CancerVax Corporation | Regulatory Cancervax Launches $5 Million Funding Round cancervax.com ↗ |
| 2023-03-16 | CancerVax Corporation | Regulatory Cancervax Files Non-Provisional Patent for Universal Cancer Treatment cancervax.com ↗ |
All press releases naming this drug 52 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CancerVax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00052130 ↗ |
| Known as | CANVAXIN | “CancerVax vaccine (CANVAXIN)” NCT00052130 ↗ |
| Modality | Vaccine | “a Polyvalent Melanoma Vaccine” NCT00052130 ↗ |